Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Corcept Therapeutics ( (CORT) ).
On November 4, 2025, Corcept Therapeutics announced its financial results for the third quarter of 2025, reporting a revenue increase to $207.6 million from $182.5 million in the same quarter of 2024. The company has expanded its oncology development programs, including new studies in various cancers, and is approaching significant clinical milestones, such as the New Drug Application for relacorilant in hypercortisolism and platinum-resistant ovarian cancer. Despite a decrease in net income compared to the previous year, Corcept is optimistic about meeting the increasing demand for its products and advancing its clinical trials.
The most recent analyst rating on (CORT) stock is a Buy with a $83.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.
Spark’s Take on CORT Stock
According to Spark, TipRanks’ AI Analyst, CORT is a Outperform.
Corcept Therapeutics’ overall stock score is driven by strong financial performance and positive earnings call sentiment. However, technical indicators suggest weak momentum, and the high P/E ratio indicates potential overvaluation. The absence of a dividend yield further impacts its valuation score.
To see Spark’s full report on CORT stock, click here.
More about Corcept Therapeutics
Corcept Therapeutics Incorporated is a commercial-stage company focused on discovering and developing medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol.
Average Trading Volume: 825,823
Technical Sentiment Signal: Buy
Current Market Cap: $7.82B
See more insights into CORT stock on TipRanks’ Stock Analysis page.